We included individuals with type 2 diabetes who received a first-ever prescription for SGLT2 inhibitors (n=53,096) or DPP4 inhibitors (n=53,521)/sulfonylureas (n=34,883) with preserved eGFR (≥60 ml/min per 1.73 m2) and normal uACR or low-level albuminuria (uACR 0–30 mg/mmol) and no prior history of heart failure or atherosclerotic CVD (ESM Fig. 1). This evidence concerns the gene SLC5A2 and heart failure.